Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: pocotrader who wrote (1333568)	12/12/2021 6:35:12 PM
From: Winfastorlose	2 Recommendations Recommended By Mick Mørmøny tntpal Read Replies (2) \| Respond to of 1576379

Three shots of Pfizer COVID vaccine 4x less effective against Omicron

To: pocotrader who wrote (1333568)	12/12/2021 7:49:55 PM
From: golfer72	1 Recommendation Recommended By Maple MAGA Respond to of 1576379

"I don't give a shit if you get the vaccine or not." So apparently you disagree with most governments who are pushing the shot including Blackface Trudeau. Interesting

To: pocotrader who wrote (1333568)	12/13/2021 12:00:16 AM
From: Broken_Clock	1 Recommendation Recommended By Winfastorlose Read Replies (2) \| Respond to of 1576379

zerohedge.com "The authors note, "Being a retrospective observational analysis, it is uncertain whether results would be reproducible in a randomized, placebo-controlled, double-blind clinical trial, but likely, since groups of ivermectin users and non-users had similar demographic characteristics, and rates were adjusted for the relevant confounding variables." We're sure the 'fact checkers' are already hard at work trying to debunk the pre-print, however they may also want to take a look at ivmmeta.com - a real-time meta analysis of 70 studies which found that Ivermectin works as a prophylaxis 83% of the time. In peer-reviewed studies, it was found effective 70% of the time as an early treatment, and just 39% of the time as a late treatment." This is even more impressive when you learn the IVM users were older on average, with 30% >50 yo versus 20% for non-IVM users. The mortality reduction is even higher looking at different age groups. 85% for 31-49 yo and 59% for >50 yo. pic.twitter.com/K6D5naybCS — Simon Vallée (@sival84) December 11, 2021